<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hematologic complications of rheumatoid arthritis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hematologic complications of rheumatoid arthritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hematologic complications of rheumatoid arthritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ehrenfeld, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Yehuda Shoenfeld, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">E William St Clair, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Rheumatoid arthritis (RA) may be associated with a range of extraarticular manifestations, with hematologic complications including anemia and other conditions with hematologic abnormalities, such as Felty syndrome and lymphoproliferative disorders, particularly lymphoma and large granular lymphocyte (LGL) leukemia. Some hematologic complications correlate with disease activity or duration of disease, some are most likely to be medication related, and some are independent of disease activity [<a href="#rid1">1</a>].</p><p>Hematologic complications of RA and their evaluation are reviewed here. The clinical manifestations of RA, including both articular and other extraarticular manifestations, are described elsewhere. (See  <a class="medical medical_review" href="/d/html/7502.html" rel="external">"Clinical manifestations of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/d/html/7511.html" rel="external">"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis"</a>.)</p><p>Felty syndrome and LGL leukemia associated with RA are also discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Felty syndrome (see  <a class="medical medical_review" href="/d/html/7482.html" rel="external">"Clinical manifestations and diagnosis of Felty syndrome"</a> and  <a class="medical medical_review" href="/d/html/7486.html" rel="external">"Drug therapy in Felty syndrome"</a> and  <a class="medical medical_review" href="/d/html/7485.html" rel="external">"Role of splenectomy for Felty syndrome"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>LGL leukemia (see  <a class="medical medical_review" href="/d/html/7489.html" rel="external">"Large granular lymphocyte leukemia in rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/d/html/4536.html" rel="external">"Treatment of large granular lymphocyte leukemia"</a>)</p><p></p><p class="headingAnchor" id="H2168504449"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H2694260387"><span class="h2">Likelihood of hematologic findings</span><span class="headingEndMark"> — </span>The following hematologic complications may be seen in people with rheumatoid arthritis (RA).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anemia of chronic disease/anemia of inflammation (ACD/AI), especially in individuals whose disease is not well controlled</p><p class="bulletIndent2"><span class="glyph">•</span>Medication-induced cytopenias, especially macrocytic anemia and neutropenia</p><p class="bulletIndent2"><span class="glyph">•</span>Iron deficiency anemia</p><p class="bulletIndent2"><span class="glyph">•</span>Vitamin B12 and folate deficiencies, which can cause mild anemia, leukopenia, and thrombocytopenia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rare</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Felty syndrome, which is associated with neutropenia and splenomegaly</p><p class="bulletIndent2"><span class="glyph">•</span>Large granular lymphocyte (LGL) leukemia</p><p class="bulletIndent2"><span class="glyph">•</span>Non-Hodgkin lymphoma, including diffuse large B cell lymphoma (DLBCL)</p><p></p><p>Many of the findings that were seen in the past have become less common as disease control has improved overall.</p><p class="headingAnchor" id="H2394771813"><span class="h2">Findings of special concern (red flags) and indications for hematologist referral</span><span class="headingEndMark"> — </span>The following are especially concerning and warrant hematologist involvement:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever and neutropenia (absolute neutrophil count [ANC] &lt;1500/microL (<a class="calc calc_professional" href="/d/html/13483.html" rel="external">calculator 1</a>)), which could indicate life-threatening infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe cytopenias (hemoglobin &lt;8 g/dL or with hemodynamic compromise; ANC &lt;1500/microL; platelet count &lt;50,000/microL) or rapidly declining cell counts, which may require urgent transfusions or other interventions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal/immature cells on the peripheral blood smear, which suggest a primary bone marrow disorder or severe infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytopenias in combination with abnormal coagulation testing, which may suggest a more serious disorder such as disseminated intravascular coagulation (DIC).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspected thromboembolic complications, which is an indication for urgent evaluation and anticoagulation.</p><p></p><p>This is not an exclusive list; other concerning findings on the history, examination, laboratory testing, or imaging should also be addressed.</p><p class="headingAnchor" id="H3441779865"><span class="h1">ABNORMAL CBC</span><span class="headingEndMark"> — </span>The complete blood count (CBC) is often abnormal in people with rheumatoid arthritis (RA). Anemia and thrombocytosis are consistent with chronic inflammation but may have other causes.</p><p class="headingAnchor" id="H2"><span class="h2">Anemia</span><span class="headingEndMark"> — </span>Anemia was very common in people with RA before the routine use of more effective disease-modifying antirheumatic drugs (DMARDs) and more effective strategies for their use in the decades following the introduction of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> in the mid-1980s. The prevalence of anemia prior to these breakthroughs was in the range of 25 to 70 percent [<a href="#rid2">2-7</a>].</p><p>Subsequent to the late 1990s, the prevalence of anemia has trended towards approximately 10 percent. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of approximately 6000 individuals with RA diagnosed between 2004 and 2016, anemia was present in 16 percent, both at the time of initial diagnosis and when re-evaluated at three years post-diagnosis [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 2000 individuals with RA who were followed over one calendar year (2009) while receiving one or more DMARDs, 199 (10 percent) had anemia [<a href="#rid9">9</a>]. These included 90 with iron deficiency anemia (45 percent of those with anemia) and 78 with anemia of chronic disease/anemia of inflammation (ACD/AI; 39 percent of those with anemia).</p><p></p><p>While anemia is common at the initial presentation of RA, it often resolves after control of active disease is achieved with antiinflammatory drugs and DMARDs [<a href="#rid10">10,11</a>]. This recovery in hemoglobin concentration ensues because the primary cause of anemia is ACD/AI, which correlates with the extent of systemic inflammation that improves with disease control. Anemia with features other than low ferritin or that does not improve with RA disease control requires further evaluation so as not to miss a second contributing factor such as vitamin B12 deficiency. (See <a class="local">'Anemia evaluation'</a> below.)</p><p class="headingAnchor" id="H3863989198"><span class="h3">Anemia causes</span><span class="headingEndMark"> — </span>People with RA can develop anemia from all of the same causes as those without RA. The following are more likely in people with RA than the general population:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia of chronic disease/anemia of inflammation (ACD/AI)</strong> – ACD/AI is probably the most common cause of anemia in people with RA. ACD/AI is typically a mild (hemoglobin range, 10 to 11 g/dL, occasionally lower), normochromic, normocytic anemia with an inappropriately low reticulocyte count. The other cell lines (white blood cells [WBCs] and platelets) are not affected. The serum ferritin level is normal to elevated and the levels of iron, transferrin, and transferrin saturation (TSAT) are generally low [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation", section on 'Testing for all individuals'</a>.)</p><p></p><p class="bulletIndent1">The mechanism of ACD/AI involves inflammatory cytokines that increase levels of hepcidin and in turn restrict iron availability for red blood cell (RBC) production. As a result, many people with newly diagnosed RA (more than 50 percent in some studies) will have mild anemia from this mechanism [<a href="#rid13">13</a>]. Treatment of RA typically improves the anemia, as discussed below. (See <a class="local">'Anemia management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Medications used to treat RA can cause anemia by several mechanisms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a>, <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a>, <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> can cause direct bone marrow suppression, often with macrocytic anemia [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonsteroidal antiinflammatory drugs (NSAIDs) and glucocorticoids may cause gastrointestinal bleeding and iron deficiency, with microcytic anemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Many antibiotics  (<a class="graphic graphic_table graphicRef109693" href="/d/graphic/109693.html" rel="external">table 1</a>) can cause autoimmune hemolytic anemia (AIHA), with an increased reticulocyte count. <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> can rarely cause AIHA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron deficiency</strong> – Iron deficiency anemia may be caused by gastrointestinal or menstrual blood loss or pregnancy. Comorbid conditions that interfere with iron absorption may also contribute, including celiac disease, <em>Helicobacter pylori</em> infection, atrophic gastritis, and bariatric surgery. Typical findings include microcytosis and low ferritin, the severity of which depend on the degree of deficiency  (<a class="graphic graphic_table graphicRef76236" href="/d/graphic/76236.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Causes and risk factors for iron deficiency'</a> and  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Stages of iron deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemolysis</strong> – Hemolytic anemia is not a typical feature of RA. Antibody-mediated (Coombs-positive) hemolytic anemia has been described infrequently, primarily in patients with Felty syndrome [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/7482.html" rel="external">"Clinical manifestations and diagnosis of Felty syndrome"</a> and  <a class="medical medical_review" href="/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pure red cell aplasia</strong> – Acquired pure red cell aplasia (PRCA) has been reported only rarely in patients with RA [<a href="#rid16">16,17</a>]; it is a form of bone marrow suppression in which erythropoiesis is severely impaired. Causes include autoantibodies, medications, and infections, as summarized in the table  (<a class="graphic graphic_table graphicRef122462" href="/d/graphic/122462.html" rel="external">table 3</a>). The anemia is normocytic and normochromic, and the reticulocyte count is very low. Bone marrow examination will show absent erythroblasts. (See  <a class="medical medical_review" href="/d/html/7120.html" rel="external">"Acquired pure red cell aplasia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Felty syndrome</strong> – Felty syndrome, a rare complication of RA, typically includes neutropenia and splenomegaly. Mild anemia and/or thrombocytopenia may also be present due to splenic sequestration of RBCs and platelets [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/7482.html" rel="external">"Clinical manifestations and diagnosis of Felty syndrome"</a> and  <a class="medical medical_review" href="/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'Hypersplenism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other deficiencies</strong> – Other deficiencies including vitamin B12 and/or folate deficiency may occur. Some case series suggest that these conditions are more common in individuals with RA than in the general population, although the reasons are unclear [<a href="#rid18">18</a>]. Checking vitamin B12 and possibly folate levels is reasonable in all individuals with RA and unexplained macrocytic anemia. Folate testing may be omitted in some cases, such as individuals with a normal gastrointestinal anatomy and a balanced diet. (See  <a class="medical medical_review" href="/d/html/7153.html" rel="external">"Causes and pathophysiology of vitamin B12 and folate deficiencies"</a>.)</p><p></p><p class="headingAnchor" id="H2384431958"><span class="h3">Anemia evaluation</span><span class="headingEndMark"> — </span>The urgency, pace, and focus of the evaluation depend on the patient's clinical presentation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Active RA</strong> – In an individual with a new presentation of RA or without good disease control who has a normochromic, normocytic anemia that is not severe (hemoglobin ≥8 to 10 g/dL) and in whom the WBC and platelet counts are normal, disease control using disease-modifying drugs may be sufficient to correct the anemia and allow a retrospective diagnosis of ACD/AI. (See  <a class="medical medical_review" href="/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation", section on 'Treatment of the underlying disorder'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microcytosis (mean corpuscular volume [MCV] &lt;80 fL)</strong> – In an individual with microcytosis, iron studies (ferritin, iron, total iron binding capacity or transferrin, and calculated TSAT) are appropriate to evaluate for possible iron deficiency. Iron deficiency is characterized by a low ferritin and low TSAT. Normal ranges for ferritin depend on whether there is an ongoing inflammatory process, as discussed separately. If iron stores are normal, evaluation for thalassemia may be appropriate. (See  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Patients with inconclusive initial testing or comorbidities'</a> and  <a class="medical medical_review" href="/d/html/4432.html" rel="external">"Microcytosis/Microcytic anemia", section on 'Approach to the evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Macrocytosis (MCV &gt;100 fL)</strong> – In an individual with macrocytic anemia, the first question is whether one of their medications can be causing macrocytosis. <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> therapy is a frequent cause of macrocytic anemia and may be associated with an MCV as high as 105 fL (occasionally higher). Mild macrocytic anemia from methotrexate is not a reason to discontinue the drug, but the vitamin B12 and folate levels should be checked, and deficiencies corrected. The reticulocyte count should also be checked, since reticulocytes are larger than mature RBCs and can increase the MCV. Severe hemolytic anemia or PRCA from a drug would be a reason to stop the drug. For patients in whom the MCV remains high (eg, &gt;101 fL) after vitamin B12 and folate deficiencies and drug-induced causes are excluded, hematology evaluation for other causes is appropriate (eg, bone marrow examination for possible myelodysplastic syndrome). (See  <a class="medical medical_review" href="/d/html/7155.html" rel="external">"Clinical manifestations and diagnosis of vitamin B12 and folate deficiency", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/d/html/7166.html" rel="external">"Macrocytosis/Macrocytic anemia", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normocytic anemia (MCV 80 to 100 fL)</strong> – Multifactorial anemia is more common in RA than in the general population, and the MCV may be normal due to a combination of conditions that independently cause it to be high or low. Because multiple causes may be present, it may be reasonable to do more extensive testing initially rather than sequentially testing for individual causes. Even if one cause of anemia is identified, testing for additional causes is appropriate in any person whose anemia does not respond to treatment as expected. If their disease is well controlled by a medication that may cause anemia, testing for iron deficiency, vitamin B12 deficiency, and other common causes of anemia may be reasonable.</p><p></p><p class="bulletIndent1">A reasonable panel of initial testing in an individual with relatively well-controlled RA and normocytic anemia includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Iron studies (serum ferritin, iron, total iron binding capacity or transferrin, and calculated TSAT), vitamin B12 and folate levels, and reticulocyte count</p><p class="bulletIndent2"><span class="glyph">•</span>Metabolic panel that addresses kidney and liver function</p><p class="bulletIndent2"><span class="glyph">•</span>Thyroid-stimulating hormone (TSH) and possibly testosterone level (in older males in whom other initial testing is unrevealing)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation of iron studies</strong> – A ferritin level &lt;30 ng/mL and/or TSAT &lt;19 percent is considered diagnostic of iron deficiency. However, iron studies may be more challenging to interpret in the setting of a chronic inflammatory condition, as ferritin is an acute phase reactant and may be increased due to inflammation. Thus, an individual with a higher ferritin may have iron deficiency. Use of a more liberal ferritin cutoff and additional testing may be helpful, including soluble transferrin receptor (sTFr) or sTFR-ferritin ratio and/or response to a therapeutic trial of iron. Staining of a bone marrow sample for iron is considered the gold standard for confirming iron deficiency, but this is rarely needed. (See  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Patients with inconclusive initial testing or comorbidities'</a> and  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Response to a therapeutic trial of iron'</a>.)</p><p></p><p>If the above testing is unhelpful and anemia remains unexplained, additional testing may include serum protein electrophoresis and evaluation for myelodysplasia or other clonal hematologic disorders, typically with bone marrow examination, especially in older individuals. Hematology referral would be appropriate if RA is well controlled and the cause of the anemia remains unclear.</p><p>These concepts and a general approach to the anemia evaluation are summarized in the figure  (<a class="graphic graphic_algorithm graphicRef130710" href="/d/graphic/130710.html" rel="external">algorithm 1</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Anemia management</span><span class="headingEndMark"> — </span>Transfusion is not likely to be needed for most people with RA and anemia. However, if anemia is severe (hemoglobin &lt;7 g/dL) or causes hemodynamic compromise, transfusions may be indicated. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a>.)</p><p>Management of anemia depends on an accurate determination of the underlying cause (see <a class="local">'Anemia causes'</a> above and <a class="local">'Anemia evaluation'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACD/AI</strong> – Disease control is the major intervention and typically is sufficient to increase the hemoglobin level. In most cases the hemoglobin returns to the normal range, or at least ≥11 g/dL (women) and ≥12 g/dL (men). (See  <a class="medical medical_review" href="/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a>.)</p><p></p><p class="bulletIndent1">In a series of 93 patients with RA, 61 (66 percent) had mild anemia at baseline (mean hemoglobin, 11.3 g/dL) [<a href="#rid19">19</a>]. Hemoglobin values increased within two weeks of active therapy (<a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> or a tumor necrosis factor [TNF] inhibitor) and continued to rise, in most cases into the normal range. Other studies have reported similar findings [<a href="#rid20">20-25</a>].</p><p></p><p class="bulletIndent1">The role of erythropoietin is very limited in RA, and it is rarely used. A systematic review from 2013 identified three randomized trials that included 133 individuals &gt;16 years with RA and anemia; one reported improvements in health-related quality of life with erythropoiesis-stimulating agents (ESAs) and one did not [<a href="#rid26">26</a>]. It noted that the safety of ESAs is unclear. Small randomized trials from the 1980s and 1990s showed that erythropoietin could increase the hemoglobin level, but these trials preceded the modern era of RA therapy [<a href="#rid27">27,28</a>]. ESAs have fallen out of favor as a treatment for ACD/AI due to other conditions as well. (See  <a class="medical medical_review" href="/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation", section on 'ESAs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medication-induced, macrocytic anemia</strong> – Administration of folate following <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> dosing is routine. Isolated macrocytosis or mild macrocytic anemia due to an RA medication without evidence of vitamin B12 or folate deficiency can be observed and monitored without stopping the drug, provided the macrocytosis and/or anemia does not progressively worsen. Worsening anemia should prompt additional evaluations, and the methotrexate dose may need to be reduced or the drug discontinued if another cause is not identified. (See  <a class="medical medical_review" href="/d/html/7166.html" rel="external">"Macrocytosis/Macrocytic anemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron deficiency</strong> – Iron repletion with oral or intravenous iron, and determination of the cause of the deficiency. (See  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemolytic anemia</strong> – Drug discontinuation is appropriate if a medication cause is suspected. Warm AIHA is treated with a glucocorticoid, often combined with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (especially if symptomatic), along with <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation, as discussed separately. (See  <a class="medical medical_review" href="/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Initial management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pure red cell aplasia</strong> – Immunosuppression is considered first-line therapy for individuals with no concurrent self-limited illness who have severe or prolonged anemia for more than three to four weeks. Hematologist input is advised. (See  <a class="medical medical_review" href="/d/html/7120.html" rel="external">"Acquired pure red cell aplasia in adults", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Felty syndrome</strong> – The management of Felty syndrome is described in detail separately. (See  <a class="medical medical_review" href="/d/html/7486.html" rel="external">"Drug therapy in Felty syndrome"</a> and  <a class="medical medical_review" href="/d/html/7485.html" rel="external">"Role of splenectomy for Felty syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other deficiencies</strong> – Repletion of the deficient vitamin and determination of the cause of the deficiency. (See  <a class="medical medical_review" href="/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a>.)</p><p></p><p>Hematologist input is appropriate if standard interventions are ineffective. The hematologist may determine that bone marrow evaluation or other specialized testing is needed to determine the cause of anemia, or that other interventions are required. (See <a class="local">'Findings of special concern (red flags) and indications for hematologist referral'</a> above.)</p><p class="headingAnchor" id="H10"><span class="h2">Neutropenia</span></p><p class="headingAnchor" id="H2156725987"><span class="h3">Neutropenia causes</span><span class="headingEndMark"> — </span>Neutropenia is typically defined as an absolute neutrophil count (ANC) &lt;1500/microL; however, the reference range depends on the individual’s Duffy antigen status. For Duffy-null individuals, the lower limit of the reference range is 1210 /microL, and some individuals will have lower neutrophil counts (referred to as Duffy-null-associated neutrophil count [DANC]). (See  <a class="medical medical_review" href="/d/html/7924.html" rel="external">"Red blood cell antigens and antibodies", section on 'Duffy antigens'</a> and  <a class="medical medical_review" href="/d/html/139725.html" rel="external">"Gene test interpretation: <i>ACKR1 </i>(Duffy blood group gene)", section on 'Reference ranges for Duffy-null and non-Duffy-null'</a> and  <a class="medical medical_review" href="/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia", section on 'Normal variants &lt;1500/microL'</a>.)</p><p>Some laboratories report the ANC; in some cases, it must be calculated by multiplying the total WBC count by the percent of neutrophils (<a class="calc calc_professional" href="/d/html/13483.html" rel="external">calculator 1</a>).</p><p>It is important to review previous ANC values when the individual was well. A decreasing ANC is of concern, even if it is not &lt;1500/microL; individuals with a decrease in ANC should have the value repeated to determine a downward trend and need for further evaluation. (See <a class="local">'Neutropenia evaluation'</a> below.)</p><p>Causes of neutropenia specific to RA include:</p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced, such as with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tumor necrosis factor (TNF) inhibitors [<a href="#rid29">29</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Interleukin (IL) 6 inhibitors [<a href="#rid29">29</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Janus kinase (JAK) inhibitors </p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">Leflunomide</a> [<a href="#rid30">30</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> [<a href="#rid31">31</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Felty syndrome</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Large granular lymphocyte (LGL) leukemia, formerly also called LGL syndrome</p><p></p><p>A literature review from 2012 identified transient neutropenia in 16 percent of individuals treated with a TNF inhibitor [<a href="#rid32">32</a>]. Another study that included 298 individuals with RA treated with a TNF inhibitor reported an episode of neutropenia in 19 percent; of these patients, 6 percent had a serious infectious complication [<a href="#rid33">33</a>]. The possibility of neutropenia is the rationale for periodic monitoring of the CBC during TNF inhibitor therapy, as discussed separately. (See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects", section on 'Neutropenia'</a>.)</p><p>A few reports have described severe delayed-onset neutropenia following <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> therapy (up to several months after administration). (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis", section on 'Late-onset neutropenia'</a>.)</p><p>Other RA therapies may cause neutropenia and/or agranulocytosis, including drugs that can lead to bone marrow suppression, such as <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (although the last is now rarely used other than for selected extraarticular complications); as well as drugs acting through other mechanisms, including <a class="drug drug_general" data-topicid="9963" href="/d/drug information/9963.html" rel="external">sulfasalazine</a>, NSAIDs, and medications used for comorbid conditions. Drugs implicated in causing neutropenia and agranulocytosis are summarized in the table  (<a class="graphic graphic_table graphicRef65507" href="/d/graphic/65507.html" rel="external">table 4</a>) and reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis", section on 'Implicated agents'</a>.)</p><p>Felty syndrome and LGL leukemia are discussed below. (See <a class="local">'Felty syndrome'</a> below and <a class="local">'Hematologic malignancies'</a> below.)</p><p class="headingAnchor" id="H2283906356"><span class="h3">Neutropenia evaluation</span><span class="headingEndMark"> — </span>The pace of the evaluation depends on the severity of the neutropenia and whether the person has signs of a serious infection. If a serious infection is present, it should be treated aggressively with appropriate antibiotics and possibly granulocyte colony-stimulating factor (G-CSF), as illustrated in the algorithm  (<a class="graphic graphic_algorithm graphicRef131569" href="/d/graphic/131569.html" rel="external">algorithm 2</a>) and discussed separately. Notably, use of G-CSF in patients with RA may trigger a disease flare. G-CSF is most important in people who do not have adequate bone marrow production of neutrophils. (See  <a class="medical medical_review" href="/d/html/88698.html" rel="external">"Management of the adult with non-chemotherapy-induced neutropenia"</a>.)</p><p>In some cases, the cause of neutropenia may be obvious, typically with drug-induced neutropenia and/or infections. Other causes may be related to RA, such as Felty syndrome or LGL leukemia, or they may be due to separate causes such as vitamin B12 deficiency. (See  <a class="medical medical_review" href="/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia"</a>.)</p><p>An approach to the evaluation includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Review prior CBCs to determine if neutropenia is chronic or new  (<a class="graphic graphic_algorithm graphicRef131569" href="/d/graphic/131569.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Review of medications and their temporal relationship to the onset of neutropenia. (See <a class="local">'Neutropenia causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Review the CBC report (and blood smear if possible) for signs myelodysplasia (dysplastic WBCs) or leukemia (immature cells).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluate for splenomegaly by physical examination, with a low threshold for obtaining an abdominal ultrasound to determine spleen size.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obtain vitamin B12 and folate levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluate for infection if appropriate (eg, if fever or other signs of active infection).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Flow cytometry to assess T cell clonality, especially if there are features of LGL leukemia (eg, immature lymphocytes, other cytopenias); clonality is present in LGL leukemia but not in Felty syndrome [<a href="#rid34">34</a>].</p><p></p><p>Much of this testing can be done by the primary clinician. For patients in whom the cause cannot be determined, and/or the neutropenia is worsening, referral a hematologist is indicated. The hematologist can review the blood smear, perform a bone marrow examination with special studies including flow cytometry, and determine the appropriateness of other evaluations for possible hematologic malignancy.</p><p class="headingAnchor" id="H2282909187"><span class="h3">Neutropenia management</span><span class="headingEndMark"> — </span>Neutropenia can be a medical emergency when associated with a severe or systemic infection.</p><p>Conversely, neutropenia may not require intervention if it is mild (ANC 1500 to 2000/microL) (<a class="calc calc_professional" href="/d/html/13483.html" rel="external">calculator 1</a>).</p><p>General management considerations include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>As with other cytopenias, addressing the underlying cause is paramount. The drug should be discontinued if a drug-induced cause is suspected and the neutropenia is severe, and G-CSF can be administered, especially if there is fever or other indication of infection. For patients in whom the neutropenia is mild (eg, not &lt;1500/microL), the patient can be observed and the drug continued, either at the same dose or with a reduced dose or less frequent dosing interval. (See <a class="local">'Neutropenia causes'</a> above and <a class="local">'Neutropenia evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with fever, appropriate antibiotics should be administered without delay. Ideally, cultures and imaging are obtained to determine the site of infection and identify the infectious organism and antibiotic sensitivities before antibiotics are started, but antibiotics should not be withheld while obtaining this testing, especially in an acutely ill individual.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neutrophil growth factors can be used to raise the ANC. G-CSF is appropriate for fever and neutropenia if the neutropenia is thought to be due to underproduction of neutrophils, especially if it is severe (ANC &lt;500/microL). Administration of G-CSF is individualized with input from the consulting hematologist. A typical dose of <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> is 5 mcg/kg daily until ANC recovery; additional details of dosing and administration are discussed separately. (See  <a class="medical medical_review" href="/d/html/8383.html" rel="external">"Introduction to recombinant hematopoietic growth factors", section on 'Dose and schedule'</a>.)</p><p></p><p>Additional considerations such as choice of antibiotic (for fever) and other interventions are presented separately. (See  <a class="medical medical_review" href="/d/html/88698.html" rel="external">"Management of the adult with non-chemotherapy-induced neutropenia"</a>.)</p><p class="headingAnchor" id="H436416857"><span class="h2">High WBC or eosinophil count</span><span class="headingEndMark"> — </span>A high white blood cell (WBC) count or high eosinophil count may be related to disease activity or another cause:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>High WBC</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>RA or infection</strong> – An inflammatory flare of RA can increase the WBC count, primarily due to an increase in neutrophils. However, a high WBC count or neutrophil count should not be attributed to RA until the patient has been evaluated for an infectious cause. WBCs above 15,000/microL are distinctly uncommon in active RA without another identifiable cause. There may be a left shift, with increased numbers of bands and other immature neutrophils.</p><p></p><p class="bulletIndent2">The extent of the evaluation depends on the person's clinical status. An acutely ill individual requires a thorough history and physical examination, cultures, chest radiograph, and other testing. An otherwise well individual may have a more limited evaluation, as long as plans for follow-up are in place. (See  <a class="medical medical_review" href="/d/html/8381.html" rel="external">"Approach to the patient with neutrophilia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drug induced</strong> – Glucocorticoids can often cause drug-induced leukocytosis due to neutrophilia. The mechanism involves combination of demargination from reduced adhesion to endothelial cells and increased release from the bone marrow. Patients with neutrophilia due to glucocorticoid use often do not have an obvious increase in early forms. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Other effects'</a> and  <a class="medical medical_review" href="/d/html/8381.html" rel="external">"Approach to the patient with neutrophilia", section on 'Medications'</a>.)</p><p></p><p class="bulletIndent2">A WBC count that persists &gt;15,000/microL in a person with RA who is receiving low to moderate doses of glucocorticoids should prompt consideration of an alternative explanation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High eosinophil count</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>RA</strong> – Significant eosinophilia occurs in some patients with RA. Extraarticular features of RA associated with eosinophilia include vasculitis, pleuropericarditis, pulmonary fibrosis, and subcutaneous nodules; gold-induced skin rash was also associated with eosinophilia [<a href="#rid35">35</a>]. Early studies suggested that eosinophilia might predict greater disease activity. Treatment may be less effective in people with mild baseline eosinophilia [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other causes</strong> – Numerous other causes of eosinophilia are possible, including parasitic infestations, allergic diseases, adrenal insufficiency, and drug-induced eosinophilia. The evaluation is presented separately. (See  <a class="medical medical_review" href="/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia"</a>.)</p><p></p><p>As noted above, hematology (or infectious diseases) referral is appropriate for individuals with significant elevations of the WBC or eosinophil count that remain unexplained after the initial evaluation. (See <a class="local">'Findings of special concern (red flags) and indications for hematologist referral'</a> above.)</p><p class="headingAnchor" id="H116341259"><span class="h2">High or low platelet count</span><span class="headingEndMark"> — </span>A mild to moderate elevation in the platelet count, typically not exceeding two to three times the person's baseline, can correlate with RA disease activity [<a href="#rid38">38,39</a>]. Extreme thrombocytosis, even counts &gt;1,000,000/microL, may be seen, often associated with extraarticular disease manifestations, particularly pulmonary involvement, peripheral neuropathy, and vasculitis [<a href="#rid40">40</a>]. The mechanism is not well understood and may include proinflammatory cytokines [<a href="#rid38">38</a>].</p><p>Thrombocytopenia is rare in RA, except when it is related to drug treatment or Felty syndrome. Among the drugs that can produce thrombocytopenia are <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, TNF antagonists, IL-6 receptor blockers (eg, <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> and <a class="drug drug_general" data-topicid="113315" href="/d/drug information/113315.html" rel="external">sarilumab</a>), and JAK inhibitors (eg, <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a>, and <a class="drug drug_general" data-topicid="122341" href="/d/drug information/122341.html" rel="external">upadacitinib</a>) [<a href="#rid41">41-44</a>]. Gold and <a class="drug drug_general" data-topicid="9747" href="/d/drug information/9747.html" rel="external">penicillamine</a> were previous causes of thrombocytopenia but are no longer commonly used [<a href="#rid45">45,46</a>].</p><p>Individuals with RA may also have other causes of high or low platelet counts unrelated to RA, which are discussed separately. (See  <a class="medical medical_review" href="/d/html/6682.html" rel="external">"Approach to the patient with thrombocytosis"</a> and  <a class="medical medical_review" href="/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a>.)</p><p class="headingAnchor" id="H2951884295"><span class="h1">FELTY SYNDROME</span><span class="headingEndMark"> — </span>Felty syndrome is classically defined as a triad:</p><p class="bulletIndent1"><span class="glyph">●</span>Rheumatoid arthritis (RA)</p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia</p><p class="bulletIndent1"><span class="glyph">●</span>Splenomegaly, although this may be absent or unappreciated in some individuals</p><p></p><p>Thus, Felty syndrome is typically suspected in an individual with RA who develops neutropenia and usually splenomegaly. The clinical manifestations and treatment of Felty syndrome are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7482.html" rel="external">"Clinical manifestations and diagnosis of Felty syndrome"</a> and  <a class="medical medical_review" href="/d/html/7486.html" rel="external">"Drug therapy in Felty syndrome"</a> and  <a class="medical medical_review" href="/d/html/7485.html" rel="external">"Role of splenectomy for Felty syndrome"</a>.)</p><p>Briefly, Felty syndrome most typically occurs in individuals with longstanding, deforming RA, with a prevalence of approximately 1 to 3 percent, although the prevalence has declined in the era of effective disease-modifying therapy [<a href="#rid47">47</a>]. People with Felty syndrome have a greater risk of developing large granular lymphocyte (LGL) leukemia than those who have RA without Felty syndrome. The mechanisms of Felty syndrome and LGL leukemia in RA are incompletely understood.</p><p>The diagnosis of Felty syndrome is made based upon clinical features after excluding other causes of neutropenia and splenomegaly such as drug-induced cytopenias, infection, lymphoproliferative disorders, or LGL leukemia. (See <a class="local">'LGL leukemia'</a> below.)</p><p>The management of Felty syndrome involves nonpharmacologic measures to reduce the risk of infection and nonbiologic and biologic disease-modifying antirheumatic drugs (DMARDs) such as <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> to control RA disease activity. Granulocyte colony-stimulating factor (G-CSF), and, rarely, splenectomy may also be used in some patients to alleviate the neutropenia. (See  <a class="medical medical_review" href="/d/html/7486.html" rel="external">"Drug therapy in Felty syndrome"</a> and  <a class="medical medical_review" href="/d/html/7485.html" rel="external">"Role of splenectomy for Felty syndrome"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">HEMATOLOGIC MALIGNANCIES</span></p><p class="headingAnchor" id="H2676913627"><span class="h2">Overview and pathogenesis</span><span class="headingEndMark"> — </span>People with rheumatoid arthritis (RA) have an increased risk for lymphoproliferative disorders, including non-Hodgkin lymphoma and large granular lymphocyte (LGL) leukemia [<a href="#rid48">48</a>]. Any individual with abnormal or immature lymphoid or myeloid cells on the blood smear should be evaluated by a hematologist. (See <a class="local">'Findings of special concern (red flags) and indications for hematologist referral'</a> above.)</p><p>A mature lymphocyte count that is persistently &gt;5000/microL often warrants additional hematologic evaluation and may herald the development of chronic lymphocytic leukemia. This requires hematologist evaluation but is not in and of itself an emergency. (See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p>The mechanism of increased risk of lymphoid malignancies is likely to include immune dysregulation and/or chronic immune activation [<a href="#rid49">49</a>]. Drugs used to treat RA, including <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, may contribute to the risk, although not all patients with RA who develop hematologic malignancies have been treated with any of these drugs. In a case-control study of 23,810 patients with RA, an increased risk of developing hematologic malignancies was associated with the use of immunosuppressive agents; the relative risks were 1.2 for methotrexate, 1.4 for azathioprine, and 2.2 for cyclophosphamide [<a href="#rid50">50</a>]. Other studies have shown similar findings [<a href="#rid51">51,52</a>]. The role of tumor necrosis factor (TNF) inhibitors in the pathogenesis of hematologic malignancies in RA is unclear. (See  <a class="medical medical_review" href="/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a> and  <a class="medical medical_review" href="/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a>.)</p><p class="headingAnchor" id="H3774336815"><span class="h2">Lymphoma</span><span class="headingEndMark"> — </span>Lymphoproliferative disorders occur with increased frequency in patients with RA; incidence and mortality rates due to leukemia or lymphoma, including non-Hodgkin lymphoma, are approximately twofold higher than expected [<a href="#rid53">53-57</a>].</p><p>The incidence of non-Hodgkin lymphoma increases as active RA persists and correlates with disease activity. As an example, in a retrospective case-controlled analysis of 378 people with RA and lymphoma and 378 matched RA controls, the risk of lymphoma increased in association with greater cumulative disease activity (ninth decile of disease activity, odds ratio [OR] 9.4, 95% CI 3.1-28.0; tenth decile of disease activity, OR 61.6, 95% CI 21.0-181.0) [<a href="#rid58">58</a>]. The most common type of lymphoma was diffuse large B cell lymphoma (DLBCL; in 48 percent); 12 percent of lymphomas tested positive for Epstein-Barr virus (EBV).</p><p class="headingAnchor" id="H4290842553"><span class="h2">LGL leukemia</span><span class="headingEndMark"> — </span>Large granular lymphocyte (LGL) leukemia (historically referred to as LGL syndrome) is a clonal lymphoproliferative disorder characterized by an increase in large granular lymphocytes (typically, 2000 to 20,000/microL). Almost all individuals with RA who develop LGL leukemia have the T cell type (T-LGL), and nearly one-third of people with T-LGL have RA. In a series of 529 individuals with RA for a median of 12 years who underwent flow cytometry, a clonal T cell population indicative of T-LGL was present in 19 (3.6 percent) [<a href="#rid59">59-61</a>].</p><p>RA often precedes the development of T-LGL leukemia, but both conditions may present concurrently. Some of these individuals fulfill the clinical criteria for Felty syndrome (see <a class="local">'Felty syndrome'</a> above). Most people with T-LGL have an indolent clinical course, and many are asymptomatic at presentation. Neutropenia is present in approximately 85 percent. Details are presented separately. (See  <a class="medical medical_review" href="/d/html/7489.html" rel="external">"Large granular lymphocyte leukemia in rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H1263260833"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116127.html" rel="external">"Society guideline links: Rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H17176236"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Common hematologic complications of rheumatoid arthritis (RA) include anemia and cytopenias. Rare complications include Felty syndrome, large granular lymphocyte (LGL) leukemia, and lymphoma. Hematologist evaluation is appropriate for individuals with immature white blood cells (WBCs) on the blood smear, unexplained findings after a standard evaluation, and abnormalities that do not improve as expected with treatment. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia</strong> – Management is based on the underlying cause, with transfusions reserved for severe anemia (hemoglobin &lt;7 g/dL or anemia with hemodynamic compromise). (See <a class="local">'Anemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ACD/AI</strong> – The most common cause of anemia is the anemia of chronic disease/anemia of inflammation (ACD/AI), which correlates with disease activity and is most often seen on initial presentation or when disease is not well controlled; disease-modifying antirheumatic drug (DMARD) therapy usually improves the hemoglobin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medications</strong> – Drug-induced bone marrow suppression often causes macrocytic anemia; the drug can be continued if anemia is mild. Drug-induced hemolytic anemia or pure red cell aplasia (PRCA) are more concerning and warrant drug discontinuation in most cases.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other causes</strong> – Multifactorial anemia may include combined iron deficiency, vitamin B12 or folate deficiency, and/or other causes. Initial testing may be broader than in the general population, including iron studies, vitamin B12 and folate levels, metabolic panel that addresses kidney and liver function, thyroid-stimulating hormone (TSH), and possibly testosterone in males  (<a class="graphic graphic_algorithm graphicRef130710" href="/d/graphic/130710.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutropenia</strong> – Neutropenia (absolute neutrophil count [ANC] &lt;1500/microL) can lead to life-threatening sepsis; neutropenia with fever is a medical emergency that may require immediate evaluation and empiric antibiotics, especially when neutrophil production is impaired (see <a class="local">'Neutropenia'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Causes</strong> – Causes include drugs (tumor necrosis factor [TNF] inhibitors, interleukin [IL] 6 inhibitors, Janus kinase [JAK] inhibitors, other RA medications, antibiotics). Rare but important causes include Felty syndrome and LGL leukemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evaluation</strong> – First, consider "red flags" that warrant immediate intervention  (<a class="graphic graphic_algorithm graphicRef131569" href="/d/graphic/131569.html" rel="external">algorithm 2</a>). If these are absent, review the blood smear and other cell counts, examine for splenomegaly, and consult hematology.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of G-CSF</strong> – If neutropenia is thought to be drug-induced, reduce the dose or stop the drug. Granulocyte colony-stimulating factor (G-CSF) can be used for active infection or fever if neutropenia is thought to be due to underproduction, especially if severe (ANC &lt;500/microL). A typical dose of <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> is 5 mcg/kg daily until ANC recovery. (See  <a class="medical medical_review" href="/d/html/88698.html" rel="external">"Management of the adult with non-chemotherapy-induced neutropenia", section on 'Treatment of infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other CBC abnormalities</strong> – Causes and diagnostic approaches to other complete blood count (CBC) abnormalities are discussed above. (See <a class="local">'High WBC or eosinophil count'</a> above and <a class="local">'High or low platelet count'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Felty syndrome</strong> – Felty syndrome is the triad of RA, neutropenia, and splenomegaly; the prevalence is 1 to 3 percent but may be lower with effective RA therapy. Diagnosis is based on clinical and laboratory features after excluding other causes of neutropenia and splenomegaly. Management includes <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> and G-CSF, if needed. Refractory disease can be treated by splenectomy. (See <a class="local">'Felty syndrome'</a> above and  <a class="medical medical_review" href="/d/html/7482.html" rel="external">"Clinical manifestations and diagnosis of Felty syndrome"</a> and  <a class="medical medical_review" href="/d/html/7486.html" rel="external">"Drug therapy in Felty syndrome"</a> and  <a class="medical medical_review" href="/d/html/7485.html" rel="external">"Role of splenectomy for Felty syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LGL leukemia</strong> – RA increases the risk for lymphoproliferative disorders, including LGL leukemia and diffuse large B cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma. Any individual with abnormal or immature lymphoid or myeloid cells on the blood smear or unexplained leukocytosis, lymphocytosis, or pancytopenia should be evaluated by a hematologist. (See <a class="local">'Hematologic malignancies'</a> above and  <a class="medical medical_review" href="/d/html/7489.html" rel="external">"Large granular lymphocyte leukemia in rheumatoid arthritis"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Klein A, Molad Y. Hematological Manifestations among Patients with Rheumatic Diseases. Acta Haematol 2021; 144:403.</a></li><li><a class="nounderline abstract_t">Hansen NE. The anaemia of chronic disorders. A bag of unsolved questions. Scand J Haematol 1983; 31:397.</a></li><li><a class="nounderline abstract_t">Rajapakse CN, Holt PJ, Perera B. Diagnosis of true iron deficiency in rheumatoid arthritis. Ann Rheum Dis 1980; 39:596.</a></li><li><a class="nounderline abstract_t">Wilson A, Yu HT, Goodnough LT, Nissenson AR. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med 2004; 116 Suppl 7A:50S.</a></li><li><a class="nounderline abstract_t">Ganna S. [The prevalence of anemia in rheumatoid arthritis]. Rev Bras Reumatol 2014; 54:257.</a></li><li><a class="nounderline abstract_t">Yuan S, Chen D, Xiao Y, et al. Factors Associated with Erosive Arthritis in Rheumatoid Arthritis and Other Connective Tissue Diseases: A Retrospective Study From a Southern Chinese Population. J Clin Rheumatol 2016; 22:22.</a></li><li><a class="nounderline abstract_t">Möller B, Scherer A, Förger F, et al. Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study. Ann Rheum Dis 2014; 73:691.</a></li><li><a class="nounderline abstract_t">Nikiphorou E, de Lusignan S, Mallen C, et al. Haematological abnormalities in new-onset rheumatoid arthritis and risk of common infections: a population-based study. Rheumatology (Oxford) 2020; 59:997.</a></li><li><a class="nounderline abstract_t">Bloxham E, Vagadia V, Scott K, et al. Anaemia in rheumatoid arthritis: can we afford to ignore it? Postgrad Med J 2011; 87:596.</a></li><li><a class="nounderline abstract_t">Nikolaisen C, Figenschau Y, Nossent JC. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J Rheumatol 2008; 35:380.</a></li><li><a class="nounderline abstract_t">Paul SK, Montvida O, Best JH, et al. Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data. Semin Arthritis Rheum 2018; 47:478.</a></li><li><a class="nounderline abstract_t">Porter DR, Sturrock RD, Capell HA. The use of serum ferritin estimation in the investigation of anaemia in patients with rheumatoid arthritis. Clin Exp Rheumatol 1994; 12:179.</a></li><li><a class="nounderline abstract_t">Chen YF, Xu SQ, Xu YC, et al. Inflammatory anemia may be an indicator for predicting disease activity and structural damage in Chinese patients with rheumatoid arthritis. Clin Rheumatol 2020; 39:1737.</a></li><li><a class="nounderline abstract_t">Farr M, Tunn EJ, Symmons DP, et al. Sulphasalazine in rheumatoid arthritis: haematological problems and changes in haematological indices associated with therapy. Br J Rheumatol 1989; 28:134.</a></li><li><a class="nounderline abstract_t">Hansen OP, Hansen TM, Jans H, Hippe E. Red blood cell membrane-bound IgG: demonstration of antibodies in patients with autoimmune haemolytic anaemia and immune complexes in patients with rheumatic diseases. Clin Lab Haematol 1984; 6:341.</a></li><li><a class="nounderline abstract_t">Dessypris EN, Baer MR, Sergent JS, Krantz SB. Rheumatoid arthritis and pure red cell aplasia. Ann Intern Med 1984; 100:202.</a></li><li><a class="nounderline abstract_t">Rodrigues JF, Harth M, Barr RM. Pure red cell aplasia in rheumatoid arthritis. J Rheumatol 1988; 15:1159.</a></li><li><a class="nounderline abstract_t">Vreugdenhil G, Wognum AW, van Eijk HG, Swaak AJ. Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoietin responsiveness. Ann Rheum Dis 1990; 49:93.</a></li><li><a class="nounderline abstract_t">Song SN, Iwahashi M, Tomosugi N, et al. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res Ther 2013; 15:R141.</a></li><li><a class="nounderline abstract_t">Padjen I, Öhler L, Studenic P, et al. Clinical meaning and implications of serum hemoglobin levels in patients with rheumatoid arthritis. Semin Arthritis Rheum 2017; 47:193.</a></li><li><a class="nounderline abstract_t">Davis D, Charles PJ, Potter A, et al. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br J Rheumatol 1997; 36:950.</a></li><li><a class="nounderline abstract_t">Papadaki HA, Kritikos HD, Valatas V, et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 2002; 100:474.</a></li><li><a class="nounderline abstract_t">Peeters HR, Jongen-Lavrencic M, Raja AN, et al. Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset. Ann Rheum Dis 1996; 55:162.</a></li><li><a class="nounderline abstract_t">Vreugdenhil G, Löwenberg B, Van Eijk HG, Swaak AJ. Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis. Eur J Clin Invest 1992; 22:488.</a></li><li><a class="nounderline abstract_t">Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58:2968.</a></li><li><a class="nounderline abstract_t">Martí-Carvajal AJ, Agreda-Pérez LH, Solà I, Simancas-Racines D. Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis. Cochrane Database Syst Rev 2013; :CD000332.</a></li><li><a class="nounderline abstract_t">Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, Swaak AJ. Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial. Ann Rheum Dis 1996; 55:739.</a></li><li><a class="nounderline abstract_t">Pincus T, Olsen NJ, Russell IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89:161.</a></li><li><a class="nounderline abstract_t">Pereckova J, Martiniakova S, Payer J, et al. Analysis of hematological parameters in rheumatoid arthritis patients receiving biological therapy: contribution to prevention of avoidable hematological complications. EXCLI J 2022; 21:580.</a></li><li><a class="nounderline abstract_t">Chan J, Sanders DC, Du L, Pillans PI. Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother 2004; 38:1206.</a></li><li><a class="nounderline abstract_t">Sames E, Paterson H, Li C. Hydroxychloroquine-induced agranulocytosis in a patient with long-term rheumatoid arthritis. Eur J Rheumatol 2016; 3:91.</a></li><li><a class="nounderline abstract_t">Bessissow T, Renard M, Hoffman I, et al. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther 2012; 36:312.</a></li><li><a class="nounderline abstract_t">Hastings R, Ding T, Butt S, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 2010; 62:764.</a></li><li><a class="nounderline abstract_t">Gorodetskiy VR, Sidorova YV, Kupryshina NA, et al. Analysis of a single-institution cohort of patients with Felty's syndrome and T-cell large granular lymphocytic leukemia in the setting of rheumatoid arthritis. Rheumatol Int 2021; 41:147.</a></li><li><a class="nounderline abstract_t">Panush RS, Franco AE, Schur PH. Rheumatoid arthritis associated with eosinophilia. Ann Intern Med 1971; 75:199.</a></li><li><a class="nounderline abstract_t">Guellec D, Milin M, Cornec D, et al. Eosinophilia predicts poor clinical outcomes in recent-onset arthritis: results from the ESPOIR cohort. RMD Open 2015; 1:e000070.</a></li><li><a class="nounderline abstract_t">Chiardola F, Schneeberger EE, Citera G, et al. Prevalence and clinical significance of eosinophilia in patients with rheumatoid arthritis in Argentina. J Clin Rheumatol 2008; 14:211.</a></li><li><a class="nounderline abstract_t">Ertenli I, Kiraz S, Oztürk MA, et al. Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatol Int 2003; 23:49.</a></li><li><a class="nounderline abstract_t">Bowman SJ. Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol 2002; 31:251.</a></li><li><a class="nounderline abstract_t">Farr M, Scott DL, Constable TJ, et al. Thrombocytosis of active rheumatoid disease. Ann Rheum Dis 1983; 42:545.</a></li><li><a class="nounderline abstract_t">Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 2003; 139:W.</a></li><li><a class="nounderline abstract_t">Coblyn JS, Weinblatt M, Holdsworth D, Glass D. Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. Ann Intern Med 1981; 95:178.</a></li><li><a class="nounderline abstract_t">Thomas D, Gallus AS, Brooks PM, et al. Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine. Ann Rheum Dis 1984; 43:402.</a></li><li><a class="nounderline abstract_t">Franck H, Rau R, Herborn G. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheumatol 1996; 15:266.</a></li><li><a class="nounderline abstract_t">Adachi JD, Bensen WG, Kassam Y, et al. Gold induced thrombocytopenia: 12 cases and a review of the literature. Semin Arthritis Rheum 1987; 16:287.</a></li><li><a class="nounderline abstract_t">von dem Borne AE, Pegels JG, van der Stadt RJ, et al. Thrombocytopenia associated with gold therapy: a drug-induced autoimmune disease? Br J Haematol 1986; 63:509.</a></li><li><a class="nounderline abstract_t">Gibson C, Berliner N. How we evaluate and treat neutropenia in adults. Blood 2014; 124:1251.</a></li><li><a class="nounderline abstract_t">Seror R, Lafourcade A, De Rycke Y, et al. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database. RMD Open 2022; 8.</a></li><li><a class="nounderline abstract_t">Klein A, Polliack A, Gafter-Gvili A. Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome. Hematol Oncol 2018; 36:733.</a></li><li><a class="nounderline abstract_t">Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008; 168:378.</a></li><li><a class="nounderline abstract_t">Hemminki K, Huang W, Sundquist J, et al. Autoimmune diseases and hematological malignancies: Exploring the underlying mechanisms from epidemiological evidence. Semin Cancer Biol 2020; 64:114.</a></li><li><a class="nounderline abstract_t">Noureldine HA, Nour-Eldine W, Hodroj MH, et al. Hematological malignancies in connective tissue diseases. Lupus 2020; 29:225.</a></li><li><a class="nounderline abstract_t">Franklin J, Lunt M, Bunn D, et al. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006; 65:617.</a></li><li><a class="nounderline abstract_t">Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37:481.</a></li><li><a class="nounderline abstract_t">Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 47:988.</a></li><li><a class="nounderline abstract_t">Wolfe F, Fries JF. Rate of death due to leukemia/lymphoma in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48:2694.</a></li><li><a class="nounderline abstract_t">Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165:2337.</a></li><li><a class="nounderline abstract_t">Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54:692.</a></li><li><a class="nounderline abstract_t">Schwaneck EC, Renner R, Junker L, et al. Prevalence and Characteristics of Persistent Clonal T Cell Large Granular Lymphocyte Expansions in Rheumatoid Arthritis: A Comprehensive Analysis of 529 Patients. Arthritis Rheumatol 2018; 70:1914.</a></li><li><a class="nounderline abstract_t">Drillet G, Pastoret C, Moignet A, et al. Large granular lymphocyte leukemia: An indolent clonal proliferative disease associated with an array of various immunologic disorders. Rev Med Interne 2023; 44:295.</a></li><li><a class="nounderline abstract_t">Semenzato G, Calabretto G, Barilà G, et al. Not all LGL leukemias are created equal. Blood Rev 2023; 60:101058.</a></li></ol></div><div id="topicVersionRevision">Topic 7512 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33221805" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hematological Manifestations among Patients with Rheumatic Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6648353" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The anaemia of chronic disorders. A bag of unsolved questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diagnosis of true iron deficiency in rheumatoid arthritis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15050886" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25627219" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : [The prevalence of anemia in rheumatoid arthritis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26693623" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Factors Associated with Erosive Arthritis in Rheumatoid Arthritis and Other Connective Tissue Diseases: A Retrospective Study From a Southern Chinese Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23505235" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31501866" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Haematological abnormalities in new-onset rheumatoid arthritis and risk of common infections: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21659451" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Anaemia in rheumatoid arthritis: can we afford to ignore it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18260177" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28947313" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8039285" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The use of serum ferritin estimation in the investigation of anaemia in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31916111" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Inflammatory anemia may be an indicator for predicting disease activity and structural damage in Chinese patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2565128" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sulphasalazine in rheumatoid arthritis: haematological problems and changes in haematological indices associated with therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6525801" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Red blood cell membrane-bound IgG: demonstration of antibodies in patients with autoimmune haemolytic anaemia and immune complexes in patients with rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6691662" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Rheumatoid arthritis and pure red cell aplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3139881" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pure red cell aplasia in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2317122" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoietin responsiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24286116" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparative evaluation of the effects of treatment with tocilizumab and TNF-αinhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28385457" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical meaning and implications of serum hemoglobin levels in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9376990" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12091338" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8712878" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1516597" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18821691" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23450527" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8984939" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2200263" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35651659" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Analysis of hematological parameters in rheumatoid arthritis patients receiving biological therapy: contribution to prevention of avoidable hematological complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187208" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Leflunomide-associated pancytopenia with or without methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27708979" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hydroxychloroquine-induced agranulocytosis in a patient with long-term rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22725726" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20535786" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neutropenia in patients receiving anti-tumor necrosis factor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33280072" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Analysis of a single-institution cohort of patients with Felty's syndrome and T-cell large granular lymphocytic leukemia in the setting of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4934278" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Rheumatoid arthritis associated with eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26509068" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Eosinophilia predicts poor clinical outcomes in recent-onset arthritis: results from the ESPOIR cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18766121" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prevalence and clinical significance of eosinophilia in patients with rheumatoid arthritis in Argentina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12634936" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pathologic thrombopoiesis of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12455813" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hematological manifestations of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6605121" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Thrombocytosis of active rheumatoid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12899609" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Severe neutropenia and thrombocytopenia associated with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6942668" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6742902" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8793258" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3110956" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Gold induced thrombocytopenia: 12 cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3089270" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Thrombocytopenia associated with gold therapy: a drug-induced autoimmune disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24869938" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : How we evaluate and treat neutropenia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35738803" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29862535" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299492" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31181268" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Autoimmune diseases and hematological malignancies: Exploring the underlying mechanisms from epidemiological evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31933408" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hematological malignancies in connective tissue diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16249224" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8147925" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The mortality of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3207388" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13130492" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Rate of death due to leukemia/lymphoma in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16287762" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The risk of lymphoma development in autoimmune diseases: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508929" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29938921" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prevalence and Characteristics of Persistent Clonal T Cell Large Granular Lymphocyte Expansions in Rheumatoid Arthritis: A Comprehensive Analysis of 529 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37087371" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Large granular lymphocyte leukemia: An indolent clonal proliferative disease associated with an array of various immunologic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36870881" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Not all LGL leukemias are created equal.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
